<DOC>
	<DOCNO>NCT01342081</DOCNO>
	<brief_summary>DE-111 ophthalmic solution evaluate superiority comparison Tafluprost 0.0015 % ophthalmic solution , non-inferiority comparison Tafluprost 0.0015 % Timolol ophthalmic solution 0.5 % use concomitantly , IOP ( intraocular pressure ) -lowering effect primary open-angle glaucoma ocular hypertension patient , multicenter , randomize , double-masked , parallel-group comparison study . Safety compare evaluate well .</brief_summary>
	<brief_title>DE-111 Against Tafluprost Ophthalmic Solution 0.0015 % Alone Concomitant Use Tafluprost Ophthalmic Solution 0.0015 % Plus Timolol Ophthalmic Solution 0.5 %</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosed primary open angle glaucoma ocular hypertension Provided sign , write informed consent 20 year age old If subject female childbearing potential , must utilize reliable contraceptive throughout study , must negative urine pregnancy test prior enrollment study . Females pregnant , nurse planning pregnancy , females childbearing potential use reliable method contraception . Presence abnormality significant illness could expect interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Primary open angle glaucoma ocular hypertension</keyword>
</DOC>